Search Results
Your search for ,WHo matches 20379 pages
Showing 14301 - 14350Pembrolizumab Survival Benefit Proves Durable in Patients With Advanced Melanoma
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
What ASCO Can Do for You—and for Our Patients
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival...
A Psychotherapist’s Approach to End-of-Life Care
BookmarkTitle: Dying: A TransitionAuthor: Monika Renz, PhD; translated by Mark Kyburz and John PeckPublisher: Columbia University PressPublication date: October 2015Price: $38.00; hardcover, 176 pages The night before Julius Caesar was assassinated, he had dinner with his friend Marcus...
In Celebration of a Remarkable Career at ASCO
In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...
Clinically Relevant Mutations Identified Through Sequencing of Cerebrospinal Fluid of Patients With CNS Cancers
Next-generation sequencing identified clinically relevant somatic alterations in cancer-associated genes in the cerebrospinal fluid of patients with central nervous system (CNS) cancers, according to a report by Pentsova et al in the Journal of Clinical Oncology. Somatic Alterations The study...
Site of Tumor Impacts Survival and Choice of Treatment in Metastatic Colorectal Cancer
In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1 “While previous studies had...
HIV-Infected Patients With Cancer May Be Likely to Receive Cancer Treatment
A study found that human immunodeficiency virus (HIV)-infected patients with cancer in the United States appear to be less likely to receive cancer treatment, regardless of insurance and other existing health conditions. The study, by researchers at the University of Utah, the National Cancer...
Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer
Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib (Xalkori), a small-molecule tyrosine kinase inhibitor. Chromosomal...
Liquid Biopsy–Based Test Appears Comparable to Standard Tissue Testing in Detecting BRAF V600 Mutations
Cell-free (cf) DNA from plasma offers a minimally invasive approach to obtain material for BRAF mutation analysis for diagnostics and response monitoring. A study by Janku et al investigating whether the detection of BRAF V600 mutations in plasma cfDNA from patients with advanced cancers using the...
French Trial Shows Benefit of Adding Short-Term Hormone Therapy to Salvage Radiotherapy for Rising PSA After Prostatectomy
In the phase III GETUG-AFU 16 trial reported in The Lancet Oncology, Carrie et al found that adding short-term androgen suppression therapy to salvage radiotherapy was associated with improved biochemical or clinical progression-free survival among patients with prostate cancer who exhibited rising ...
Specific Version of the FCGR2A Gene Identifies Colorectal Cancer Patients Likely to Benefit Most From Cetuximab
Among patients with metastatic colorectal cancer harboring normal forms of the KRAS gene, only those who had two copies of a specific version of the FCGR2A gene (FCGR2A H/H) had a statistically significant increase in median overall survival when cetuximab (Erbitux) treatment was added to best...
Physician Recommendation May Influence Racial Disparity in BRCA1/2 Testing in Women With Breast Cancer
A disparity in BRCA1/2 testing between white and black women was influenced by patient-reported physician recommendation, in a population-based study reported by McCarthy et al in the Journal of Clinical Oncology. Study Details The study involved data from 3,016 women (69% white, 31% black) in...
Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion
In a phase II study reported in The Lancet Oncology, Stilgenbauer et al found that the BCL2 inhibitor venetoclax (Venclexta) produced a high response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion (del [17p]). The study supported the recent...
Use of Complementary and Alternative Medicine Affects Breast Cancer Chemotherapy Initiation
Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND,...
T-Cell Bim Levels May Reflect Responses to Anti–PD-1 Cancer Therapy
A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, MD, PhD, and published by Dronca et al in JCI Insight. “Immune checkpoint...
ASCO 2016: Autologous Stem Cell Transplant Remains Relevant in Multiple Myeloma, Even in Era of Novel Agents
Early findings from a phase III clinical trial (EMN02/HO95 MM) showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents. This is the largest study reported to...
FDA Approves Atezolizumab for Advanced Urothelial Carcinoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to atezolizumab (Tecentriq) for the treatment of urothelial carcinoma, the most common type of bladder cancer. This is the first programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor to be...
ASCO 2016: PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma in KEYNOTE-001
Long-term follow-up from a phase Ib trial (KEYNOTE-001) in newly diagnosed and previously treated patients with advanced melanoma showed that 40% of patients were alive 3 years after starting the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda), with similar 36-month...
ASCO 2016: Left- vs Right-Sided Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer
For a longer-form examination of these data, click here. A retrospective analysis from a large, federally funded clinical trial finds that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal...
AATS 2016: Strategies for Increasing Survival In Soft-Tissue Sarcoma Patients With Lung Metastases Undergoing Resection
Up to 50% of patients with soft-tissue sarcoma develop lung metastases. Effective systemic therapies for metastatic soft-tissue sarcoma are currently limited; when possible, pulmonary metastasectomy is the preferred treatment. However, guidelines for the performance of pulmonary metastasectomy for...
AATS 2016: Stage IIIA NSCLC Survival Rates Improved When Care Included Four Specific Quality Measures
Current guidelines from the National Comprehensive Cancer Network (NCCN) and American College of Chest Physicians (ACCP) recommend that operable patients with clinical stage IIIA non–small cell lung cancer (NSCLC) should receive induction chemotherapy (with or without concurrent radiotherapy) ...
ATS 2016: Untreated Severe Obstructive Sleep Apnea Associated With Increased Aggressiveness of Cutaneous Melanoma
Untreated severe obstructive sleep apnea is associated with increased aggressiveness of malignant cutaneous melanoma, according a multicenter, prospective study. The new study, which involved researchers from 24 teaching hospitals that are part of the Spanish Sleep and Breathing Network, was...
Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Metastatic Breast Cancer
The addition of bevacizumab (Avastin) to first-line endocrine therapy with letrozole improved progression-free survival but increased toxicity among postmenopausal women with hormone receptor–positive metastatic breast cancer, according to the results of the phase III CALGB 40503/Alliance...
Addition of Ixazomib to Lenalidomide/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
Moreau et al found that adding the oral proteasome inhibitor ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone significantly prolonged progression-free survival among patients with relapsed, refractory, or relapsed and refractory multiple myeloma. They reported the findings from the...
FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima), in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment...
Same vs Different Order for Second Readings of Mammograms in Rates of Breast Cancer Detection
A new study has found there is no decline over time in the accuracy of medical staff who analyze mammogram scans for indications of breast cancer. Researchers at the University of Warwick investigated whether detection rates dropped toward the end of each batch of mammogram readings. The study...
FDA Grants Selumetinib Orphan Drug Designation for Adjuvant Treatment of Differentiated Thyroid Cancer
AstraZeneca announced on May 12 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the investigational MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer. Differentiated...
AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial
A promising new test is detecting prostate cancer more precisely than current tests by identifying molecular changes in the prostate-specific antigen (PSA) protein, according to Cleveland Clinic research presented at the 111th Annual Scientific Meeting of the American Urological Association (AUA)...
Women With Breast Cancer Who Are Knowledgeable About Their Tumor Characteristics Are More Likely to Receive Guideline-Recommended Treatment
Women with breast cancer who know the characteristics of their tumor are more likely to receive the treatment recommended for their type of cancer, Dana-Farber Cancer Institute investigators reported in a new study. The study, published by Freedman et al in the Journal of Oncology Practice, is...
Adjuvant MAGE-A3 Immunotherapeutic Shows No Benefit in Resected MAGE-A3–Positive NSCLC
In the phase III MAGRIT trial reported in The Lancet Oncology, Vansteenkiste et al found that adjuvant therapy with the MAGE-A3 cancer immunotherapeutic did not improve disease-free survival in patients with resected MAGE-A3–positive non–small cell lung cancer (NSCLC). The...
AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase estrogen receptor–positive breast cancer ...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer...
Corporate Angel Network’s 50,000th Patient Flight Benefits Young Retinoblastoma Patient
On April 14, 2016, an 18-month-old patient with cancer named Baron Yerby flew home to Atlanta after receiving treatment at Memorial Sloan Kettering Cancer Center. However, instead of flying on a crowded commercial plane with the potential for immune deficiency issues, he and his parents flew on a...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
Inspirational Stories for Cancer Survivors
Surveys indicate that cancer survivors have varying desires regarding the kind of support they want. Some patients find support groups very helpful as they deal with the host of issues in survivorship. Others want to distance themselves from the “world of cancer.” Studies also show that...
FDA Launches First Campaign Focused on Dangers of Smokeless Tobacco Among Rural Teens
The U.S. Food and Drug Administration (FDA) has announced it is expanding its award-winning “The Real Cost” campaign to educate rural white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco...
Breakthrough Therapy Efforts Result in Unprecedented Success
Friends of Cancer Research (Friends) and the U.S. Food and Drug Administration (FDA) have been working together for many years on an idea known as breakthrough therapy, and it has produced results beyond anyone’s hopes. Said Ellen Sigal, PhD, Friends Chair and Founder, “When we were first talking...
Clinical Trials Actively Recruiting Patients With Ewing Sarcoma
Phase I Study Title: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy-Refractory Ewing Sarcoma Study Type: Interventional/nonrandomized/single-group assignment Study Sponsor and Collaborators: University of Louisville Purpose: To examine the...
Sixteen Leaders in Breast Cancer Research Join Susan G. Komen as Advisors
Susan G. Komen recently welcomed 16 leaders in breast cancer research and advocacy who will serve as Komen Scholars—an international advisory group that helps to guide Komen’s research and scientific programs, education and advocacy work, and public health efforts in the United States and abroad....
Expert Point of View: Julie Margenthaler, MD and Mahmoud El-Tamer, MD
Press briefing moderator Julie Margenthaler, MD, of Washington University Siteman Cancer Center, St. Louis, who is Communications Committee Chair for the American Society of Breast Surgeons, agreed that surveillance would be acceptable only within a clinical trial, and one is underway now....
Recurrences Observed in More Than 50% of Inadequately Treated Patients With Ductal Carcinoma in Situ
A mid much debate about the potential for overly aggressive treatment of ductal carcinoma in situ comes a study that gives one pause. According to research presented at the 17th Annual Meeting of the American Society of Breast Surgeons, more than half of all women with ductal carcinoma in situ that ...
Sheldon M. Feldman, MD, Named President of ASBrS
Sheldon M. Feldman, MD, was named President of the American Society of Breast Surgeons (ASBrS) at the organization’s 2016 Annual Meeting in Dallas, Texas. Dr. Feldman is the Chief of Breast Surgery at NewYork-Presbyterian/Columbia University Medical Center and the Vivian L. Milstein Associate...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
Risk Factors for Acute Pancreatitis in Children/Young Adults With Acute Lymphoblastic Leukemia
In a study reported in the Journal of Clinical Oncology, Liu et al found that Native American ancestry, older age, higher cumulative dose of asparaginase, and a rare variant of the CPA2 gene increased risk for pancreatitis in children/young adults with acute lymphoblastic leukemia (ALL). Study...
Donor Spotlight: Gateway for Cancer Research
The Conquer Cancer Foundation of ASCO is collaborating with Gateway for Cancer Research (Gateway) to fund a 2016 and 2017 Young Investigator Award through the Conquer Cancer Foundation Grants and Awards program. “Conquer Cancer Foundation is grateful for the generous support from Gateway and...
